Loading…
← CockpitCompetitor Analysis › 9969.HK InnoCare Pharma Ltd.Open in the cockpit ↗

InnoCare Pharma Ltd.9969.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese biotech developing targeted therapies for cancer and autoimmune disease, led by BTK-inhibitor orelabrutinib.

≈ A Chinese BeiGene-style oncology/immunology biotechMomentum weak 37
Mkt cap
$2.01B
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$8.99M
20-day average traded
Fwd P/E
32.2×
forward earnings
ROIC−WACC
+16.6 pp
WACC 10.0%
Hurdle
-343 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · HKDHK$10.82
1D-2.4%
1W-9.1%
1M-13.4%
3M-24.2%
6M-10.3%
YTD-12.0%
1Y-24.5%
ATR %5.5%
52w lowhigh33.2% off high

What InnoCare Pharma does

Chinese biotech developing targeted therapies for cancer and autoimmune disease, led by BTK-inhibitor orelabrutinib.

Sells orelabrutinib mainly in China, where hospital access depends on the national reimbursement list, which trades a negotiated lower price for broader coverage. Licensing is a second route: partners can pay upfront and milestone fees for rights outside China. It listed in Hong Kong in 2020 and added a Shanghai STAR Market listing in 2022.

In one line: A Chinese BeiGene-style oncology/immunology biotech.

Products and services

  • Orelabrutinib (BTK inhibitor)
  • Oncology pipeline
  • Autoimmune drug pipeline

Customers

  • Hospitals/oncologists and rheumatologists in China

Where it sits in the supply chain

  • Biotechnology
  • Small-molecule/targeted oncology drugs
  • Autoimmune therapeutics

What could go right

  • New indication approvals
  • Overseas licensing

What could go wrong

  • Clinical trial risk
  • Reimbursement/pricing pressure

Moat: narrow (IP / patents, first-mover approval). Own BTK inhibitor approved in China with patent protection.

Headquarters: Beijing, China · Founded: 2015 · Employees: 1,259

Named competitors

InnoCare Pharma at a glance

Size InnoCare Pharma (9969.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.01B, the 410th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.82 on 18 Nov 2026.

Performance Over six months the shares fell 10.3%, against -1.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 146.3% over the last twelve months (peer median +10.7%); the operating margin is 35.2% (peer median 20.9%).

Valuation It trades at 32.2× forward earnings against a peer median of 18.1× (5th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +341%, so the hurdle is -343 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.6 points above its cost of capital (10.0% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 979969.HK 91
Six months, rebased to 100: InnoCare Pharma against the median of its 20 peers (local-currency closes).

InnoCare Pharma financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$3.80BHK$2.56BHK$1.08BHK$810MHK$722M
Revenue growth—+136%+34%+12%—
Gross profitHK$3.53BHK$2.24BHK$827MHK$571MHK$473M
EBITDAn/aHK$619M-HK$475M-HK$673M-HK$824M
Net incomeHK$1.53BHK$697M-HK$478M-HK$698M-HK$1.03B
Free cash flowHK$412MHK$146M-HK$336M-HK$886M-HK$887M
Capital expenditureHK$152MHK$76.1MHK$84.8MHK$281MHK$431M
Total debtHK$2.49BHK$1.79BHK$1.68BHK$1.82BHK$385M

Quarterly statements and history in the cockpit →

InnoCare Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%009420300436603456ERIS603707600285BHVNONESOURCEHRMYH0260020145400512SHILPAMED214450ALIVUSPFIZER300009600211COHANCE9969.HK6-month return →1-month return →
Up and to the right = strong over both horizons. InnoCare Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×603456ERIS600285ONESOURCEHRMYH02600201SHILPAMED214450ALIVUSCOHANCE9969.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InnoCare Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%603456ERIS603707HRMY9969.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InnoCare Pharma is the large dot.

InnoCare Pharma competitors and peer comparison

Head to head with its named competitors (9969.HK vs 1801.HK vs 9926.HK vs AZN.L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
InnoCare Pharma 9969.HK$2.01B-10%+146%35%32.2×-2.0%
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
Akeso 9926.HK$7.01B-48%+42%-25%n/an/a
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%

How InnoCare Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InnoCare Pharma against its 20 peers (data as of 18 Nov 2026)
Measure9969.HKPeer medianRank in peer set
1-month return-13.4%+2.7%3rd lowest of 21
6-month return-10.3%-1.3%9th lowest of 21
Distance from 52-week high-33.2%-28.2%6th lowest of 21
Revenue growth (TTM)+146.3%+10.7%highest of 20
Operating margin35.2%20.9%2nd highest of 20
Forward P/E32.2×18.1×5th most expensive of 18
Growth the price implies (Req g, 7 yrs)-2.0%3.2%4th least demanding of 14
Growth delivered (Del g)+341.1%+14.1%highest of 14
Hurdle (Req g minus delivered)-343.1 pp-12.4 ppleast demanding of 14
ROIC minus cost of capital+16.6 pp+0.1 pp6th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a

Questions

Who are InnoCare Pharma's main competitors?
Named competitors: BeiGene (private or unlisted), Innovent Biologics (1801.HK), Akeso (9926.HK), AstraZeneca (AZN.L), Eli Lilly (LLY), Johnson & Johnson (JNJ). The cockpit's measured peer set (industry) also includes Hanall Biopharma (009420.KS), Fujian Cosunter Pharmaceutical (300436.SZ), Zhejiang Jiuzhou Pharmaceutical (603456.SS), Eris Lifesciences (ERIS.NS), Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Henan Lingrui Pharmaceutial (600285.SS).
Is InnoCare Pharma expensive compared with its peers?
On forward p/e it trades at 32.2× against a peer median of 18.1×, 5th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +341%, so the hurdle is -343 pp: the price already allows for a slowdown.
How has InnoCare Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -10.3% against -1.3% for the median peer; over one year -24.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.